Ocumetics Technology Announces $2.5 Million Brokered LIFE Offering Led by Centurion One Capital

(TheNewswire)

NOT FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATIONIN THE UNITED STATES

Calgary, AB – TheNewswire - November 25, 2025 – Ocumetics Technology Corp. (“ Ocumetics ” or the“ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that it hasentered into an agreement with Centurion One Capital Corp. (the“ Lead Agent ”) as lead agent and sole bookrunner, in connection with abrokered private placement to raise up to $2,500,000 (the“ Offering “) through the sale of up to 3,472,222 units of theCorporation (“ Units “) at an issue price of $0.72 per Unit(the “ IssuePrice ”) on a best efforts basis. Each Unitshall consist of one common share in the capital of the Corporation(each, a “ Share ”) and one common share purchase warrant (each, a“ Warrant ”). Each Warrant will entitle theholder thereof to acquire one common share of the Corporation (each, a“ Warrant Share ”) at a price of $0.90 per Warrant Share at any time for aperiod of three (3) years following the Closing Date (as definedherein).

In addition, the Corporation will grant the Lead Agentan option to sell up to an additional 520,833 Units at the OfferingPrice for additional gross proceeds of up to $375,000 (the“ Agent’sOption ”) on the same terms and conditions asset out herein. The Agent’s Option is exercisable in whole or inpart at any time, up to two business days prior to the Closing Date.

The gross proceeds of the Offering are expected to beused to fund the Corporation’s first-in-human clinical trials, forongoing research and development and for general corporate purposes. Although the Corporation intends to use the proceeds of the offeringas described above, the actual allocation of proceeds may vary fromthe uses set out above, depending upon future operations, events oropportunities.

The Units will be offered for sale (i) by way ofprivate placement pursuant to the listed issuer financing exemptionunder section 5A.2 of National Instrument 45-106 – Prospectus Exemptions , as amended and supplemented by Coordinated Blanket Order45-935 – Exemptions fromCertain Conditions of the Listed Issuer FinancingExemption (the “ Listed Issuer FinancingExemption ”) in British Columbia, Alberta andOntario, (ii) in the United States pursuant to an exemption from theregistration requirements of the United States Securities Act of 1933,as amended (the “ U.S.Securities Act ”), and applicable U.S. statesecurities laws, and (iii) in jurisdictions outside of Canada and theUnited States as mutually agreed to by the Corporation and the LeadAgent, provided it is understood that no prospectus filing,registration or comparable obligation arises in such otherjurisdiction. The securities issued under the Listed Issuer FinancingExemption will not be subject to a statutory hold period pursuant toapplicable Canadian securities laws .

There is an offering document (the “ Offering Document ”) related to this Offering that canbe accessed under the Corporation’s profile at www.sedarplus.ca andon the Corporation’s website at www.ocumetics.com. Prospectiveinvestors should read this Offering Document before making aninvestment decision.

The Offering is expected to close on or around December11, 2025, or such other date as agreed upon between the Corporationand the Lead Agent (the “ Closing Date ”) and is subject to certainconditions, including, but not limited to, thereceipt of all necessary approvals including the approval of the TSXVenture Exchange (the “ Exchange ”).

It is anticipated that certain insiders of theCorporation, the Lead Agent and certain affiliates may acquire Unitsin the Offering. Any participation by insiders in the Offering willconstitute a "related party transaction" as defined underMultilateral Instrument 61-101 – Protection of Minority Security Holders inSpecial Transactions (" MI 61-101 "). TheCorporation expects such participation will be exempt from the formalvaluation and minority shareholder approval requirements of MI 61-101as neither the fair market value of the Units subscribed for by theinsiders, nor the consideration for the Units paid by such insiders,is expected to exceed 25% of the Corporation's marketcapitalization.

This news release does not constitute an offer to sellor a solicitation of an offer to buy any of the securities in theUnited States. The securities have not been and will not be registeredunder the U.S. Securities Act or any state securities laws and may notbe offered or sold within the United States or to U.S. persons unlessregistered under the U.S. Securities Act and applicable statesecurities laws or an exemption from such registration isavailable.

ABOUT OCUMETICS

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QBO) is a Canadian research and product development companythat is dedicated to developing advanced vision correction solutionsthat enhance the quality of life for patients. Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.

Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry. Ocumetics hasdeveloped an intraocular lens that fits within the natural lenscompartment of the eye potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s natural muscleactivity to shift focus from distance to near, providing clear visionat all distances without the help of glasses or contact lenses.

Additional information is available atwww.ocumetics.com and www.sedarplus.ca.

For further information, please contact:

Mr. Dean Burns

President and CEO

Tel: 817-874-7564

About Centurion One Capital

Centurion One Capital's mission is to ignite theworld's most visionary entrepreneurs to conquer the greatestchallenges of tomorrow, fueling their ambitions with transformativecapital, unparalleled expertise, and a global network of influentialconnections. Every interaction is guided by our core values ofrespect, integrity, commitment, excellence in execution, anduncompromising performance. We make principal investments, drawing onthe time-honored principles of merchant banking, where alignedincentives forge enduring partnerships. Centurion One Capital: Asuperior approach to investment banking.

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this release.

CAUTIONARY NOTE REGARDINGFORWARD-LOOKING STATEMENTS:

This news release contains certain “forward-lookinginformation” within the meaning of applicable Canadian securitieslegislation. Generally, forward-lookinginformation can be identified by the use of forward-lookingterminology such as “plans”, “expects” or “does notexpect”, “is expected”, “budget”, “scheduled”,“estimates”, “forecasts”, “intends”, “anticipates” or“does not anticipate”, or “believes”, or variations of suchwords and phrases or state that certain actions, events or results“may”, “could”, “would”, “might” or “will betaken”, “occur” or “be achieved”. Forward-looking statements include, but are not limited to,statements with respect to the completion of theOffering and the anticipated Closing Datethereof; the expected receipt of regulatory and Exchange approvalsrelating to the Offering; the expected proceeds of the Offering andthe anticipated use thereof; and any other activities, events ordevelopments that the companies expect or anticipate will or may occurin the future.

Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.

Copyright (c) 2025 TheNewswire - All rights reserved.